---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122316"
form_type: "8-K"
ticker: "TRVI"
cik: "0001563880"
company_name: "Trevi Therapeutics, Inc."
filed_at: "2024-11-06T23:59:59+00:00"
generated_at: "2026-05-30T04:32:43.150181+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Trevi Therapeutics reports Q3 net loss of $13.2M; completes Phase 2a RIVER enrollment

## Summary
- Net loss of $13.2M for Q3 2024 vs $7.7M loss in Q3 2023; R&D expenses rose to $11.2M from $6.3M.
- Cash, cash equivalents and marketable securities of $65.5M at quarter end; expected runway into H2 2026.
- Completed enrollment in Phase 2a RIVER trial for refractory chronic cough; topline results expected Q1 2025.
- Enrolled 50% of planned 160 patients in Phase 2b CORAL trial for chronic cough in IPF; SSRE outcome expected Dec 2024; topline H1 2025.

## SEC filing metadata
- accession: 0000950170-24-122316
- form_type: 8-K
- ticker: TRVI
- cik: 0001563880
- company_name: Trevi Therapeutics, Inc.
- filed_at: 2024-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563880/000095017024122316/0000950170-24-122316-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563880/000095017024122316/trvi-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122316
- JSON: https://secwatch.observer/filing/0000950170-24-122316.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122316.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.